

ASX ANNOUNCEMENT

19 February 2024

Reset offers withdrawn *Reset to remain LGP subsidiary*



Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") advises that Reset Mind Sciences Limited ("**Reset**") has withdrawn its offers under the Reset Prospectus lodged with ASIC on 9 November 2023 as set out in the Supplementary Prospectus attached to this announcement.

The withdrawal follows the AIM stock exchange's decision that as Psychedelic Assisted Psychotherapy ("**PAP**") is not currently permitted in the United Kingdom, UK funds cannot invest and Reset is not currently capable of listing on a UK stock exchange.

While disappointing, the Company believes that with the rapid advance of psychedelics globally, PAP services will be legal in the UK in the near term at which time the Company will re-engage with regulators. In the meantime, the Company will continue to progress its globally leading psychedelics business.

Reset's share registry has been instructed to promptly return all subscription funds to investors.

Following Reset's decision to withdraw the offers, the Company has withdrawn Resolution 1 relating to the in-specie distribution of Reset shares from its upcoming general meeting on 21 February 2024, with the general meeting to solely consider Resolution 2 confirming the appointment of the Company's auditor BDO.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomass per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

Supplementary Prospectus

Reset Mind Sciences Limited
(ACN 659 154 480)

Important information

This is a supplementary prospectus (**Supplementary Prospectus**) which is intended to be read with the prospectus dated 9 November 2023 (**Prospectus**) issued by Reset Mind Sciences Limited (ACN 659 154 480) (**Company**).

This Supplementary Prospectus is dated 19 February 2024 and was lodged with ASIC on that date. ASIC, ASX and their respective officers take no responsibility for the contents of this Supplementary Prospectus. This Supplementary Prospectus should be read together with the Prospectus.

Capitalised terms and abbreviations that have not otherwise been defined in this Supplementary Prospectus have the meaning given in the Prospectus. This Supplementary Prospectus will be issued with the Prospectus as an electronic prospectus, copies of which can be downloaded from the website of the Company at <https://www.resetmind.com.au/>.

This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisors without delay.

1. Withdrawal of the Offers

The purpose of this Prospectus is to notify investors that the Directors of the Company have resolved to withdraw the Offers as set out in the Prospectus.

This Prospectus formally withdraws the Offers. All application monies received will be returned to Applicants as soon as practicable. There is no need for those parties to request a refund. The Company advises that the Offers are now closed and that the indicative timetable for the Offers no longer applies. The expiry date of the Prospectus is brought forward to the date of this Supplementary Prospectus, being 19 February 2024. Accordingly, no Securities will be issued, and the Company will not be accepting any further Applications.

2. Resignation of Director

On 5 February 2024, the Honourable Cheryl Edwardes AM resigned as a Director of the Company, effective immediately.

3. Appointment of Director

On 5 February 2024, Paul Long was appointed as a Director, effective immediately.

This Supplementary Prospectus is intended to be read with the Prospectus dated 9 November 2023 issued by Reset Mind Sciences Limited (ACN 659 154 480).

4. **Consents**

The Company confirms that as at the date of this Supplementary Prospectus, each of the parties that have been named as having consented to being named in the Prospectus have not withdrawn that consent.

5. **Authorisation**

This Supplementary Prospectus is issued by the Company and its issue has been authorised by the Directors.

The Directors believe that the Prospectus when read together with this Supplementary Prospectus contains all the information that would be required by sections 710 and 711 of the Corporations Act and does not contain any material statement that is misleading or deceptive.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn that consent.



Paul Long
Executive Chair

Dated: 19 February 2024